Compare Stocks: QNTM, FRMM, ZYBT, and IBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FRMM Forum Markets	$5.85 +11.4%	$5.42	$1.76 ▼ $174.60	$78.32M	1.38	784,483 shs	135,130 shs
IBIO iBio	$1.47 +3.2%	$1.61	$0.56 ▼ $3.82	$72.78M	1.31	1.25 million shs	432,708 shs
QNTM Quantum Biopharma	$2.88 -5.7%	$3.88	$2.07 ▼ $31.91	$18.40M	0.43	291,623 shs	224,230 shs
ZYBT Zhengye Biotechnology	$1.26 -5.0%	$1.08	$0.62 ▼ $13.08	$59.90M	-2.18	1.72 million shs	91,158 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FRMM Forum Markets	+1.74%	-5.23%	-12.79%	+6.92%	+524,999,900.00%
IBIO iBio	+1.43%	-2.07%	-15.48%	-11.80%	+141,999,900.00%
QNTM Quantum Biopharma	+5.54%	+2.69%	-13.11%	-43.10%	-87.13%
ZYBT Zhengye Biotechnology	0.00%	-13.07%	+105.82%	+40.74%	-74.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FRMM Forum Markets	$5.85 +11.4%	$5.42	$1.76 ▼ $174.60	$78.32M	1.38	784,483 shs	135,130 shs
IBIO iBio	$1.47 +3.2%	$1.61	$0.56 ▼ $3.82	$72.78M	1.31	1.25 million shs	432,708 shs
QNTM Quantum Biopharma	$2.88 -5.7%	$3.88	$2.07 ▼ $31.91	$18.40M	0.43	291,623 shs	224,230 shs
ZYBT Zhengye Biotechnology	$1.26 -5.0%	$1.08	$0.62 ▼ $13.08	$59.90M	-2.18	1.72 million shs	91,158 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FRMM Forum Markets	+1.74%	-5.23%	-12.79%	+6.92%	+524,999,900.00%
IBIO iBio	+1.43%	-2.07%	-15.48%	-11.80%	+141,999,900.00%
QNTM Quantum Biopharma	+5.54%	+2.69%	-13.11%	-43.10%	-87.13%
ZYBT Zhengye Biotechnology	0.00%	-13.07%	+105.82%	+40.74%	-74.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FRMM Forum Markets	2.50	Moderate Buy	$10.00	70.97% Upside
IBIO iBio	3.13	Buy	$5.00	241.30% Upside
QNTM Quantum Biopharma	1.00	Sell	N/A	N/A
ZYBT Zhengye Biotechnology	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest QNTM, FRMM, ZYBT, and IBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2026	FRMM Forum Markets	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/20/2026	ZYBT Zhengye Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
7/2/2026	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
6/30/2026	FRMM Forum Markets	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	IBIO iBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/11/2026	ZYBT Zhengye Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
6/8/2026	IBIO iBio	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
6/8/2026	IBIO iBio	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
6/5/2026	IBIO iBio	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/29/2026	ZYBT Zhengye Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
5/29/2026	FRMM Forum Markets	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold

(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FRMM Forum Markets	$6.55M	11.96	N/A	N/A	$12.59 per share	0.46
IBIO iBio	$400K	181.95	N/A	N/A	$0.90 per share	1.63
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	$1.34 per share	N/A
ZYBT Zhengye Biotechnology	$116.36M	0.51	N/A	N/A	$0.93 per share	1.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FRMM Forum Markets	-$450.52M	-$36.07	N/A	36.56	N/A	N/A	-242.09%	-135.46%	N/A
IBIO iBio	-$18.38M	-$0.58	N/A	N/A	N/A	N/A	-53.86%	-46.48%	9/4/2026 (Estimated)
QNTM Quantum Biopharma	-$26.17M	-$8.25	N/A	N/A	N/A	N/A	-941.54%	-224.41%	8/6/2026 (Estimated)
ZYBT Zhengye Biotechnology	-$9.98M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest QNTM, FRMM, ZYBT, and IBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	N/A	QNTM Quantum Biopharma	-$0.4116	N/A	N/A	N/A	N/A	N/A
5/14/2026	Q1 2026	FRMM Forum Markets	N/A	-$3.64	N/A	-$3.58	N/A	$2.86 million
5/12/2026	Q3 2026	IBIO iBio	-$0.06	-$0.07	-$0.01	-$0.06	$0.02 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FRMM Forum Markets	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FRMM Forum Markets	0.15	6.19	6.19
IBIO iBio	N/A	11.88	11.88
QNTM Quantum Biopharma	N/A	0.63	0.63
ZYBT Zhengye Biotechnology	0.03	1.14	0.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FRMM Forum Markets	4.07%
IBIO iBio	7.90%
QNTM Quantum Biopharma	1.24%
ZYBT Zhengye Biotechnology	N/A

Insider Ownership

Company	Insider Ownership
FRMM Forum Markets	25.20%
IBIO iBio	2.75%
QNTM Quantum Biopharma	8.53%
ZYBT Zhengye Biotechnology	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FRMM Forum Markets	7	13.39 million	10.02 million	N/A
IBIO iBio	100	49.68 million	48.31 million	N/A
QNTM Quantum Biopharma	N/A	6.40 million	5.85 million	N/A
ZYBT Zhengye Biotechnology	278	47.39 million	N/A	N/A

QNTM, FRMM, ZYBT, and IBIO Headlines

Recent News About These Companies

Zhengye Biotechnology Stock Short Interest Report | NASDAQ:ZYBT | Benzinga

July 23, 2026 | benzinga.com

Zhengye Biotechnology Addresses Unusual Nasdaq Trading Activity

July 21, 2026 | tipranks.com

Zhengye Biotechnology says no material events behind unusual trading activity (NASDAQ: ZYBT)

July 21, 2026 | msn.com

Zhengye Biotechnology Holding Limited Says It Is Unaware of Material Non-Public Information Amid Unusual Trading Activity

July 21, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity

July 21, 2026 | globenewswire.com

Why Zhengye Biotechnology Holding Limited (ZYBT) Stock Is Up Today

July 20, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Ltd. Class A

July 13, 2026 | cnn.com

Zhengye Biotechnology Faces Nasdaq Minimum Bid Price Deficiency After May 29 Notice

June 4, 2026 | tipranks.com

Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

June 4, 2026 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

April 28, 2026 | prnewswire.com

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure Effective April 7, 2026

April 6, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure

April 6, 2026 | globenewswire.com

Zhengye Biotechnology Holding Ltd ZYBT

March 28, 2026 | morningstar.comM

Zhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGM

March 25, 2026 | tipranks.com

Zhengye Biotechnology Director Resigns, Nasdaq Independence Deficiency to Be Addressed at March AGM

February 23, 2026 | tipranks.com

Zhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to Shareholders

February 11, 2026 | markets.businessinsider.com

Zhengye Biotechnology Holding Limited Highlights 2025 Achievements and 2026 Strategic Plan in Shareholder Letter

February 10, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to Shareholders

February 10, 2026 | globenewswire.com

Why Zhengye Biotechnology Holding Limited’s (ZYBT) Stock Is Up 5.27%

January 11, 2026 | aaii.comA

Is Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 3.8% Concerning?

September 14, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM, FRMM, ZYBT, and IBIO Company Descriptions

Forum Markets NASDAQ:FRMM

$5.85 +0.60 (+11.41%)

Closing price 03:59 PM Eastern

Extended Trading

$5.86 +0.01 (+0.10%)

As of 04:10 PM Eastern

Forum Markets Inc is a digital asset platform modernizing capital markets through the tokenization of institutional-grade real-world assets on Ethereum. The company structures cash-generating assets on blockchain-based infrastructure to facilitate liquidity, investor access, and primary and secondary market activity. It combines traditional asset management practices with digital market infrastructure to support the origination, distribution, and trading of real-world assets.

iBio NASDAQ:IBIO

$1.46 +0.05 (+3.17%)

Closing price 03:59 PM Eastern

Extended Trading

$1.46 0.00 (0.00%)

As of 04:10 PM Eastern

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Quantum Biopharma NASDAQ:QNTM

$2.88 -0.17 (-5.70%)

Closing price 03:58 PM Eastern

Extended Trading

$2.88 0.00 (-0.03%)

As of 04:10 PM Eastern

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Zhengye Biotechnology NASDAQ:ZYBT

$1.26 -0.07 (-4.96%)

Closing price 03:59 PM Eastern

Extended Trading

$1.27 +0.01 (+0.87%)

As of 04:10 PM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNTM, FRMM, ZYBT, and IBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNTM, FRMM, ZYBT, and IBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNTM, FRMM, ZYBT, and IBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM, FRMM, ZYBT, and IBIO Company Descriptions

Forum Markets NASDAQ:FRMM

iBio NASDAQ:IBIO

Quantum Biopharma NASDAQ:QNTM

Zhengye Biotechnology NASDAQ:ZYBT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNTM, FRMM, ZYBT, and IBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNTM, FRMM, ZYBT, and IBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNTM, FRMM, ZYBT, and IBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM, FRMM, ZYBT, and IBIO Company Descriptions

Forum Markets NASDAQ:FRMM

iBio NASDAQ:IBIO

Quantum Biopharma NASDAQ:QNTM

Zhengye Biotechnology NASDAQ:ZYBT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools